Contents
Market Overview
Austria maintains one of Europe’s most tightly controlled medical cannabis frameworks, governed by the Austrian Narcotics Act (Suchtmittelgesetz, SMG). The SMG permits the production, acquisition, processing, transport, possession, import, and export of narcotic substances for medical or scientific purposes, explicitly including medical cannabis.
Under this legislation, the Austrian Agency for Health and Food Safety (AGES) is the sole entity authorised to cultivate and possess cannabis for the production of medicinal products. This centralised model effectively excludes private-sector cultivation and distribution, positioning Austria as a state-controlled medical cannabis producer within the European market.
Each year, AGES cultivates several hundred kilograms of cannabis flower, which is primarily exported to Germany for processing into dronabinol (Δ9-THC). Portions of this processed dronabinol are then re-imported into Austria for domestic pharmaceutical use.
Austria’s market is defined by pharmaceutical precision rather than commercial expansion, with medical cannabis treatment almost entirely restricted to dronabinol-based magistral preparations.
Regulatory Framework
Austria’s Narcotics Act (SMG) forms the legal foundation of its medical cannabis policy. It authorises the use of cannabis-derived substances solely for:
- Medical purposes (via prescription)
- Scientific research and pharmaceutical development
The SMG grants exclusive cultivation and possession rights to AGES, which operates under the supervision of the Federal Ministry of Health.
Key framework characteristics include:
- State monopoly on cultivation and primary production — no private companies are licensed to grow cannabis.
- Strict import/export control, managed through AGES and approved pharmaceutical partners.
- Authorised product form: dronabinol (Δ9-THC) only, available as compounded oil or capsules through pharmacies.
- No medical cannabis flower or extract products are permitted for patient use.
This closed, government-led system distinguishes Austria from neighbouring countries such as Germany and the Czech Republic, where private sector cultivation and wider product access are permitted.
Patient Access
Product Availability:
Austria’s medical cannabis system is centred around dronabinol preparations compounded in pharmacies under magistral prescription.
Two primary formulations are available:
- Semi-synthetic dronabinol (available since 2004)
- 95% pure plant-derived dronabinol, extracted from cannabis cultivated by AGES (available since 2015)
Prescription Rules:
- Dronabinol prescriptions must be written by a senior physician.
- Each prescription requires strict case-by-case approval, ensuring medical necessity and prior exhaustion of standard therapies.
- Prescriptions are typically limited in duration and dosage, subject to specialist review.
Common Indications:
Dronabinol therapy is most often prescribed for:
- Spasticity and paralysis (e.g., multiple sclerosis and other neurological disorders)
- Chronic pain unresponsive to conventional treatment (including cancer and neurodegenerative diseases)
- Loss of appetite, nausea, and vomiting related to chemotherapy or AIDS
While Austria’s legal framework allows for medical use, patient access remains limited, and cannabis-based treatments are prescribed infrequently compared to other European markets.
Industry and Supply Chain
All medical cannabis cultivation in Austria is conducted by AGES, with output dedicated to the production of dronabinol for both domestic use and export.
Supply Chain Dynamics:
- Cultivation: Controlled exclusively by AGES under EU-GMP conditions.
- Export: Cannabis flower shipped primarily to Germany for dronabinol extraction.
- Re-import: Finished dronabinol returned to Austria for pharmaceutical compounding and prescription.
This circular export-import system underscores Austria’s reliance on international pharmaceutical partners for processing and formulation, despite its domestic cultivation capability.
No other companies currently hold licences for medical cannabis production or distribution within Austria, and there are no plans to liberalise the framework in the near term.
Outlook
Austria’s medical cannabis market remains pharmaceutical in scope, limited in scale, and dominated by dronabinol. With no access to flower or full-spectrum extracts, patient treatment options are significantly narrower than in neighbouring European states.
Given the government’s preference for centralised control and the absence of legislative reform discussions, substantial market growth is unlikely in the short term. However, Austria will continue to play a technical role in the European medical cannabis supply chain through its export of high-quality raw material to Germany for processing.
In the long term, alignment with broader EU trends — particularly increased patient access and the diversification of product types — would require legislative amendment of the SMG, which currently appears politically improbable.
